eligibility_summary
Eligibility: Adults (≥18) with chronic inflammatory rheumatic disease who have received ≥3 IV infliximab infusions, have no flare/progression preventing continuation, and are covered by national insurance. Exclusions: inability to comply per physician, under curatorship/tutorship, or pregnant.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Drug/intervention: Switch from IV infliximab to subcutaneous infliximab (Remsima, CT‑P13 SC) 120 mg every 2 weeks, type: chimeric IgG1 monoclonal antibody, TNF‑α inhibitor. Mechanism: binds soluble and transmembrane TNF‑α, preventing TNFR1/2 engagement, suppresses NF‑κB signaling, reduces downstream pro‑inflammatory cytokines (e.g., IL‑1, IL‑6), adhesion molecules, and leukocyte recruitment, can mediate ADCC/CDC against TNF‑expressing cells. Additional procedures: monitoring anti‑infliximab antibodies and trough levels (immunogenicity/PK). Cells/pathways targeted: TNF‑α/TNFR–NF‑κB axis in macrophages/monocytes, activated T cells, dendritic cells, synovial fibroblasts and endothelial cells, impacts osteoclastogenesis (RANKL pathway).